51 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2036. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2036
Next term end
28
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2039 · High confidence
Also notable
Ends Feb 2040 · High confidence
Also notable
Ends Apr 2036 · High confidence
Anti-SIRP-Alpha Antibodies and Methods of Use Thereof
US 11,779,642
Cited by 18 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Anti-Sirpa Antibodies and Methods of Use Thereof
US 11,319,373
Cited by 16 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2040.
Anti-Sortilin Antibodies and Methods of Use Thereof
US 10,087,255
Cited by 25 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 4 to 6, 2026 · next Dec 4
- 2 fees due Apr 1 to 10, 2027 · next Apr 1
- 1 fee due Aug 13, 2027The maintenance fee for Anti-Mertk Antibodies and Methods of Use Thereof (US 11,897,968) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for ANTI-SIGLEC-7 Antibodies and Methods of Use Thereof (US 10,590,198) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for ANTI-SIGLEC-5 Antibodies and Methods of Use Thereof (US 11,965,023) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Anti-SIRPa Antibodies and Methods of Use Thereof (US 11,976,119) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 16, 2026
What they patent
The 5 largest of its 28 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Anti-Sortilin Antibodies and Methods of Use Thereof (2016) | 6 in force | to May 2036 |
| Anti-Sortilin Antibodies and Methods of Use Thereof (2019) | 3 in force | to Jun 2040 |
| ANTI-MS4A4A Antibodies and Methods of Use Thereof | 3 in force | to May 2040 |
| Anti-Sirpa Antibodies and Methods of Use Thereof | 3 in force | to Feb 2040 |
| Anti-Mertk Antibodies and Methods of Use Thereof | 2 in force | to Apr 2042 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,084,875 | ANTI-TREM2 Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,110,327 | Anti-TREM1 Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,087,255 | Anti-Sortilin Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,308,718 | Anti-Sortilin Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,428,150 | Anti-Sortilin Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,208,488 | Methods of Increasing Progranulin Levels Using Anti-Sortilin Antibodies In force · High confidence | In force | High confidence | |
| US 11,339,223 | Methods of Use of Anti-Sortilin Antibodies for Treating a Disease, Disorder, or Injury In force · High confidence | In force | High confidence | |
| US 11,186,645 | Isolated Nucleic Acids Encoding Anti-Sortilin Antibodies In force · High confidence | In force | High confidence | |
| US 11,174,313 | ANTI-CD33 Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,136,390 | ANTI-CD33 Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 51: 36 applications pending · 23 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.